 So we know, looking over the last 25 years, that the bulk of innovation in the pharmaceutical arena has come from smaller biotech companies, right, who are spending, over the course of developing their products, a fraction of what the big companies are spending. And the reaction of the big companies of big pharma to that problem is to spend even more money